EDITORIAL

6923  Evolving role of FDG-PET/CT in prognostic evaluation of resectable gastric cancer
De Raffele E, Mirarchi M, Cuicchi D, Lecce F, Cola B

6927  Staging chronic pancreatitis with exocrine function tests: Are we better?
Sperti C, Moletta L

MINIREVIEWS

6931  How to perform gastrointestinal ultrasound: Anatomy and normal findings
Atkinson NSS, Bryant RV, Dong Y, Maaser C, Kucharzik T, Maconi G, Asthana AK, Blaivas M, Goudie A, Gilja OH,
Nuernberg D, Schreiber-Dietrich D, Dietrich CF

6942  Dysphagia: Thinking outside the box
Philpott H, Garg M, Tomic D, Balasubramanian S, Sweis R

6952  Role of endoscopic ultrasound in idiopathic pancreatitis
Somani P, Sunkara T, Sharma M

ORIGINAL ARTICLE

Basic Study

6962  Delayed and short course of rapamycin prevents organ rejection after allogeneic liver transplantation in rats
Pilon C

6973  Adipose-derived stromal cells resemble bone marrow stromal cells in hepatocyte differentiation potential
in vitro and in vivo

6983  Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-
induced acute hepatic dysfunction
Wang WW, Zhang Y, Huang XB, You N, Zheng L, Li J

6995  Mitofusin-2 mediated mitochondrial Ca\textsuperscript{2+} uptake 1/2 induced liver injury in rat remote ischemic
perconditioning liver transplantation and alpha mouse liver-12 hypoxia cell line models
Expression of annexin II in gastric carcinoma and its role in gastric cancer metastasis
Han F, Shrestha S, Huang H, Lv HY, Nie C, Lin L, Lu ML

Risk factors for postoperative recurrence after primary bowel resection in patients with Crohn’s disease

Trends and outcomes of pancreaticoduodenectomy for periampullary tumors: A 25-year single-center study of 1000 consecutive cases

Testing for hepatitis B virus alone does not increase vaccine coverage in non-immunized persons
Boyd A, Bottero J, Carrat F, Gozlan J, Rougier H, Girard PM, Lacombe K

Gastric adenocarcinoma of fundic gland type spreading to heterotopic gastric glands
Manabe S, Mukaisho K, Yasuoka T, Usui F, Matsuyama T, Hirata I, Boku Y, Takahashi S

High-grade myofibroblastic sarcoma in the liver: A case report
Wen J, Zhao W, Li C, Shen JY, Wen TF
ABOUT COVER

Editorial board member of World Journal of Gastroenterology, Jorg Kleeff, MD, Professor, Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale), Halle (Saale) 06120, Germany

AIMS AND SCOPE

World Journal of Gastroenterology (WJG) is a peer-reviewed open access journal. WJG was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The WJG Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of WJG is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. WJG is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (WJG) is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports® cites the 2016 impact factor for WJG as 3.365 (5-year impact factor: 3.176), ranking WJG as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX

Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Xiang Li
Responsible Electronic Editor: Ya Jin Me
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 9001 E. Seventh Str., Long Beach, CA 90822, United States

EDITORIAL BOARD MEMBERS

All editorial board members resources online at http://www.wjgnet.com/1007-9327/editorialboard.htm

EDITORIAL OFFICE

Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, United States
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

PUBLISHER

Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, United States
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

PUBLICATION DATE

October 14, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at http://www.wjgnet.com/bpg/guideinfo/204

ONLINE SUBMISSION

http://www.f6publishing.com
Staging chronic pancreatitis with exocrine function tests: Are we better?

Cosimo Sperti, Lucia Moletta

Cosimo Sperti, Lucia Moletta, Department of Surgery, Oncology and Gastroenterology, 3rd Surgical Clinic, University of Padua, 35128 Padua, Italy

ORCID number: Cosimo Sperti (0000-0002-7869-8715); Lucia Moletta (0000-0003-4041-5721).

Author contributions: Sperti C and Moletta L conceived the study and drafted the manuscript; both authors approved the final version of the article.

Conflict-of-interest statement: The authors have no conflict of interest to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Cosimo Sperti, Professor, Department of Surgery, Oncology and Gastroenterology, 3rd Surgical Clinic, University of Padua, via giustiniani 2, 35128 Padua, Italy. csperti@libero.it
Telephone: +39-49-8218845
Fax: +39-49-8218821

Received: July 26, 2017
Peer-review started: July 27, 2017
First decision: August 30, 2017
Revised: September 7, 2017
Accepted: September 19, 2017
Article in press: September 19, 2017
Published online: October 14, 2017

Abstract

Chronic pancreatitis (CP) is an inflammatory disease of the pancreas evolving in progressive fibrotic disruption of the gland with exocrine and endocrine pancreatic insufficiency. Although imaging features of CP are well known, their correlation with exocrine pancreatic function tests are not obvious, particularly in the early stage of the disease. There are many clinical classification of CP, all suggested for better distinguish and manage different forms based on etiological and clinical factors, and severity of the disease. Recently, a new classification of CP has been suggested: the M-ANNHEIM multiple risk factor classification that includes etiology, stage classification and degree of clinical severity. However, more accurate determination of clinical severity of CP requires a correct determination of exocrine function of the pancreas and fecal fat excretion. Recently, Kamath et al demonstrated that the evaluation of exocrine pancreatic function by acid steatocrit and fecal elastase-1 (EF-1) was helpful, but EF-1 was able to detect exocrine pancreatic insufficiency in more patients, upgrading some patients in higher stage of disease according to M-ANNHEIM classification. So, EF-1 is a more accurate test to determine exocrine pancreatic insufficiency and to stage chronic pancreatitis in the M-ANNHEIM classification. On the contrary, EF-1 determination shows low sensitivity in detecting exocrine pancreatic insufficiency in early stage of the disease.

Key words: Chronic pancreatitis; Exocrine pancreatic insufficiency; Fecal elastase-1; Pancreatic function tests; Steathorrea

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Classification of chronic pancreatitis is useful for planning adequate diagnosis and management of the disease, particularly in the early detection and prevention of related-complications. Recognition of pancreatic exocrine insufficiency is useful for graduating severity of chronic pancreatitis in modern classification systems, and, fecal elastase determination appears the better method in term of simplicity and sensitivity to stage exocrine function of the pancreas. However, sensitivity of elastase-1 is low in early stage of chronic pancreatitis, and, new diagnostic tools or combination of different procedures are needed to better stage pancreatic function.


INTRODUCTION

Chronic pancreatitis (CP) is the most commonly known cause of pancreatic exocrine insufficiency (PEI)[1]. Every patient with a new diagnosis of CP should be screened for PEI and in order to detect maldigestion prior to the occurrence of overt clinical symptoms, the presence of PEI should be evaluated annually in patients with CP. PEI can lead to poor quality of life, steathorrea, abdominal pain and malabsorption, and, early diagnosis of PEI is important to prevent malnutrition-related complications. Many tests are nowadays available for the diagnosis of PEI, but each one has some diagnostic limitations. As a consequence, PEI is still underdiagnosed and undertreated. In addition to its clinical relevance, PEI represents an helpful method for staging CP in different classification systems. The M-ANNHEIM classification is a new system for staging and grading the severity of CP[2]. The M-ANNHEIM classification system is based on the categorization determined by etiological factors, clinical stage and severity of CP. This system constitutes a simple, objective, accurate and non-invasive method for clinicians which combines the influence and interaction of several risk factors on the course of the disease. These multiple (M) risk factors included the subsets of alcohol consumption (A), nicotin consumption (N), nutritional factors (N), hereditary factors (H), effenter pancreatic duct factors (E), immunological factors (I), and various rare miscellaneous and metabolic (M) factors[2]. The M-ANNHEIM staging of CP is divided into an asymptomatic phase (stage 0) and a symptomatic phase (stages I, II, III, IV) of the disease[2]. The latter phase represents the period of clinically evident chronic inflammation of the pancreas. The evaluation of the symptomatic phases of CP is based on pain and on the presence and degree of PEI[2]. An accurate evaluation of PEI is therefore necessary to validate the diagnosis and allow the proper treatment of the disease. In fact, a correct diagnosis of PEI suggests the pancreatic enzyme replacement therapy (PERT) and it is essential to monitor the efficacy of treatment in order to avoid complications of CP. Only few studies in the literature have compared the different diagnostic power of the tests available to evaluate PEI, and only few data are available for determining their role in the present staging system of CP.

STUDY ANALYSIS

In the recent issue of the World Journal of Gastroenterology, Kamath et al[3] reported a prospective analysis comparing two tests for PEI to use in M-ANNHEIM staging for pancreatitis. In this study, 116 patients with CP were included. PEI was analyzed by fecal elastase-1 (FE-1) value and fecal fat excretion by the acid steatocrit method. Based on the results of the two tests, the patients were separately categorized as per M-ANNHEIM stages. Among the 116 patients with CP, the presence of PEI was evident in 61 (52.5%) and 79 (68.1%) by the acid steatocrit method and FE-1, respectively. A statistically significant difference was seen between the M-ANNHEIM stages as classified separately by acid steatocrit and the FE-1. The Authors concluded that FE-1 estimation permits better staging of pancreatitis by the M-ANNHEIM classification, since it diagnosed a higher number of patients with exocrine pancreatic insufficiency. They recommend the use of FE-1 test for staging CP by the M-ANNHEIM classification. The study of Kamath et al[3] is interesting because it deals with the assessment of PEI, which still remains a diagnostic challenge in patients affected by CP.

The ideal test for the diagnosis of PEI should be accurate, non-invasive, widely available and easy to perform. In our Center, in twenty years of experience, we observed 325 patients with a diagnosis of CP, and among them 253 received surgery[4,5]. In this period, different tests were used to diagnose PEI (fecal fat excretion, p-aminobenzoic acid test, coefficient of fat absorption, fecal chymotrypsin)[6-9], and in more recent years they have been replaced by FE-1 test. Nowadays, two different groups of tests (direct and indirect tests) are available for the diagnosis of PEI[1] (Table 1). Among direct tests, the most sensitive method is derived from the aspiration of the pancreatic secretions during secretin-cholecystokinin/ cerulein administration[7]. However, this test is invasive and it is available only in few specialized centers[7]. Among indirect test, the coefficient of fat absorption (CFA), the fecal-elastase-1 determination and the acid steatocrit test are the most frequently used[7]. FDA have approved treatments for PEI based on randomized...
controlled trials that used CFA to define PEI[8]. The CFA is also useful to monitor pancreatic enzyme replacement therapy (PERT). The CFA requires patients to maintain a strict diet containing 100 g of fat per day over five days, and to collect the total amount of stools excreted over the last three days[9]. A CFA < 93% is considered pathological[9]. However, this test is not easy to perform, it is difficult to control the amount of fat consumed, especially in alcoholic patients, and collection of faeces is unpleasant and cumbersome for patients. Fecal Elastase-1 (FE-1) is an indirect assessment of the pancreatic secretion. This test is easy to perform, widely available and only requires a small stool sample for analysis[10]. However, FE-1 test is not able to exclude mild to moderate PEI, and there is no consensus concerning the ideal cut-off for PEI in patients with CP: figures of < 15, 50, 100 and 200 mg/g have been proposed, and a threshold of 200 mg/g has been used most frequently in accordance with the intended use label of the test[11]. The acid steatocrit method is a quantitative measurement of fat expressed as a proportion of an entire centrifugated homogenized stool sample; it correlates well with the 72 h quantitative faecal fat estimation[12]. However, the acid steatocrit method has some disadvantages which include a lack of standardization of the test and the possible effect of dietary fat intake during the sample collection[12].

Other tests are currently available. The 13 C-Mixed Triglyceride Breath test (TGBT) is a valid alternative to the CFA, both for the diagnosis of PEI and for evaluating the efficacy of PERT in clinical practice[13]. Modifications of the test may allow the detection of mild to moderate PEI[13]. However, the test also has limitations in terms of specificity (false positive results in non-pancreatic fat malabsorption), it is not easily available since it is commercialized only in few European countries. Pancreatic secretion volume can be evaluated semiquantitatively by secretin enhanced-MRCP (s-MRCP)[14]. Pancreatic secretion evaluated by this technique correlates with FE-1 test results; however, its sensitivity for PEI is as low as 69%[14]. In addition, there is very limited evidence supporting this technique for the diagnosis of PEI in clinical practice.

In conclusion, many tests are available for the diagnosis and evaluation of PEI in CP, but every test has some limits and pitfalls. In particular, a diagnostic, non-invasive method to differentiate mild and moderate PEI is still required. Further studies are needed to identify the ideal method in the diagnostic setting of PEI.

**PERSPECTIVE**

Accurate staging of pancreatitis is crucial to study both the natural history of the disease and the effect of treatment. In the study by Kalmath et al[3], acid steatocrit and FE1 were compared, while other standard tests like CFA or the 13 C-Mixed Triglyceride Breath test were not considered. It would be interesting in future studies to investigate the comparative usefulness of these tests comprehensively. Moreover, it is reasonable to believe that the additional use of biomarkers could improve the staging systems and this aspect should be explored in future studies. Recently, it has been reported that serum monocyte chemoattractant protein-1 levels were lower in patients with CP and PEI as compared to patients with CP without PEI[15]. A panel of 6 serum miRNA has been recently suggested as potential useful investigation for diagnosis of CP, especially for the early diagnosis of CP[16]. Future studies concerning the association of tests, such as pancreatic function tests, biomarkers or radiological-endoscopic imaging, could be helpful for the early detection of CP.

**REFERENCES**


2. Schneider A, Löhr JM, Singer MV. The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying
Sperti et al. Pancreatic function tests


17 P- Reviewer: Machado M, Fujino Y, Peng SY, Sharma V
S- Editor: Gou SX
L- Editor: A
E- Editor: Ma YJ